TABLE 3.
Patient characteristics after CAR-T treatment.
| Characteristics | Non-PTR | PTR | p value |
|---|---|---|---|
| N | 11 | 14 | |
| Age (years) | 25 (16–66) | 29 (15–65) | 0.979 |
| Sex | — | — | 0.695 |
| Male | 6 (54.5%) | 6 (42.9%) | — |
| Female | 5 (45.5%) | 8 (57.1%) | — |
| BSA (kg/m2) | 1.65 (1.35–1.86) | 1.57 (1.42–1.93) | 0.851 |
| WBC count (109) before CAR-T | 6.4 (1.8–38.3) | 3.95 (0.2–75.1) | 0.373 |
| Hb count (g/L) before CAR-T | 77.27 ± 34.83 | 84.36 ± 22.07 | 0.541 |
| Platelet count (109) before CAR-T | 75.73 ± 54.602 | 71.50 ± 63.92 | 0.863 |
| Bone marrow blasts before CAR-T | — | — | 0.689 |
| <50% | 4 (36.4%) | 7 (50.0%) | — |
| ≥50% | 7 (63.6%) | 7 (50.0%) | — |
| Bone marrow blasts percentage (median) | 70% (6–84%) | 58% (0–92%) | 0.647 |
| Gene mutation | — | — | 0.645 |
| Normal | 6 (54.6%) | 9 (64.3%) | — |
| BCR-ABL | 1 (9%) | 3 (21.4%) | — |
| MLL arrangement | 2 (18.2%) | 1 (7.1%) | — |
| Other abnormalities | 2 (18.2%) | 1 (7.2%) | — |
| Cycles of prior therapy | — | — | 1.000 |
| <3 | 5 (45.5%) | 7 (50.0%) | — |
| ≥3 | 6 (54.5%) | 7 (50.0%) | — |
| Duration of first remission | — | — | 0.487 |
| <1 year | 11 (100%) | 12 (85.7%) | — |
| ≥1 year | 0 (0%) | 2 (14.3%) | — |
| No. of relapse | — | — | 1.000 |
| <2 | 6 (54.5%) | 7 (50.0%) | — |
| ≥2 | 5 (45.5%) | 7 (50.0%) | — |
| Prior allo-HSCT | — | — | 0.288 |
| No | 8 (72.7%) | 13 (92.9%) | — |
| Yes | 3 (27.3%) | 1 (7.1%) | — |
| Extramedullary involvement | — | — | 0.695 |
| No | 5 (45.5%) | 8 (57.1%) | — |
| Yes | 6 (54.5%) | 6 (42.9%) | — |
| Complete remission | — | — | 0.407 |
| No | 2 (18.2%) | 5 (35.7%) | — |
| Yes | 9 (81.8%) | 9 (64.3%) | — |
| No.of tocilizumab | — | — | 0.241 |
| 0 | 6 (54.5%) | 4 (28.6%) | — |
| 1 | 1 (9.1%) | 4 (28.6%) | — |
| 2 | 4 (36.4%) | 6 (42.9%) | — |
| Corticosteroid | — | 0.208 | |
| No | 9 (81.8%) | 7 (50%) | — |
| Yes | 2 (18.2%) | 7 (50%) | — |
| Improvement of neutrophil deficiency within 30 days | — | — | 1.000 |
| No | 5 (45.5%) | 6 (42.9%) | — |
| Yes | 6 (54.4%) | 8 (57.1%) | — |
| Recovery of neutrophil deficiency within 3 months | — | — | 0.180 |
| No | 1 (9.1%) | 5 (35.7%) | — |
| Yes | 10 (90.9%) | 9 (64.3%) | — |
| Improvement of platelet within 30 days | — | — | 1.000 |
| No | 8 (72.7%) | 10 (71.4%) | — |
| Yes | 3 (27.3%) | 4 (28.6%) | — |
| Recovery of platelet within 3 months | — | — | 0.033 |
| No | 1 (9.1%) | 8 (57.1%) | |
| Yes | 10 (90.9%) | 6 (42.9%) | |
| Infection | 0.099 | ||
| No | 9 (81.8%) | 6 (42.9%) | — |
| Yes | 2 (18.2%) | 8 (57.1%) | — |
| Highest temperature during CAR-T treatment (°C) | 39.96 ± 0.69 | 40.54 ± 0.63 | 0.039 |
| Highest level of C-reaction protein during CAR-T treatment (mg/L) | 142.41 ± 104.10 | 149.47 ± 58.67 | 0.843 |
| CRS grade | — | — | 0.005 |
| ≤2 | 8 (72.7%) | 2 (14.3%) | — |
| ≥3 | 0 (0%) | 3 (21.4%) | — |